Satellos Bioscience posts investor deck outlining SAT-3247 muscle-regeneration approach for Duchenne dystrophyPUBT·Aug 19 at 11:42 PMMSLE-0.43%
MSCL: SAT-3247 shows early clinical promise for DMD, with strong safety, efficacy, and financial backingQuartr·Aug 19 at 12:27 PMMSLE-0.43%
Satellos Q2 2026 loss widens as R&D spending rises on SAT-3247 BASECAMP, TRAILHEAD trials, company saysPUBT·Aug 13 at 04:21 PMMSLE-0.43%
Satellos Q2 FY26 net loss widens to USD 11.7 million; R&D expense more than doubles to USD 9.6 millionPUBT·Aug 13 at 04:02 PMMSLE-0.43%
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress | MSLE Stock NewsStockTitan·Aug 13 at 08:02 AMMSLE-0.43%
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study UpdateMarket Beat·Jul 10 at 02:02 PMMSLE-0.43%
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goalrttnews·Jul 10 at 11:15 AMABBV-1.09%VANI-0.35%
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidencebenzinga_article·Jul 8 at 08:34 AMMSLE-0.43%
Satellos Bioscience posts investor deck on SAT-3247 muscle-regeneration approach for Duchenne muscular dystrophyPUBT·Jul 8 at 07:27 AMMSLE-0.43%
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 | MSLE Stock NewsStockTitan·Jul 7 at 09:30 PMMSLE-0.43%
